Hepatitis B patients are a large group in mainland China, especially with over 90 million hepatitis B in mainland China, and disease management of these patients is particularly important. Standardized antiviral therapy with nucleoside analogs can maximize the control of viral replication, inhibit the ongoing damage to the liver, delay liver fibrosis, improve liver function, and reduce the risk of liver cancer, which is critical to the survival time of hepatitis patients. The most important point of standardized nucleoside analogue antiviral therapy is “standardization”. “This means strictly following the guidelines for antiviral therapy, insisting on the first-line drug of choice: entecavir (ETV) or tenofovir (TDF and TAF); adhering to a long course, strictly following antiviral therapy to normalize the virus and then continuing to consolidate for 36 months (in patients without cirrhosis); for patients with cirrhosis, it is even more important to Adhere to the long-term course; adhere to the regular review, that is, adhere to the initial stage of antiviral treatment, the virus down to the normal check value before, monthly review hepatitis B virus index and liver function, after the virus is normal, every 3 months review the virus index, if found that the virus rebound, immediately screen the virus variation site, according to the different variation site selection of appropriate antiviral drugs. In addition, AFP, PIVKA and ultrasound should be checked regularly to prevent and detect tumors while monitoring the viral index. The choice of doctor and hospital is also very important. It is recommended to choose the infection department or liver disease department of the local tertiary hospital, fix a doctor or specialist with good reputation, follow up regularly, establish medical files, and have regular and planned examination and treatment.